Cargando…

Incidence and predictors of hypoglycemia in Japanese patients with type 2 diabetes treated by insulin glargine and oral antidiabetic drugs in real-life: ALOHA post-marketing surveillance study sub-analysis

BACKGROUND: Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA), an observational, non-interventional, 24-week post-marketing surveillance study in Japanese patients with type 2 diabetes (T2DM) having uncontrolled glycemic control, demonstrated that basal supported oral therapy (BOT) with insulin gla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Odawara, Masato, Kadowaki, Takashi, Naito, Yusuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931675/ https://www.ncbi.nlm.nih.gov/pubmed/24528773 http://dx.doi.org/10.1186/1758-5996-6-20

Ejemplares similares

Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis
por: Kadowaki, Takashi, et al.
Publicado: (2012)

Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study
por: Tsukube, Shoko, et al.
Publicado: (2015)

Correction: Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis
Publicado: (2014)

Correction: Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis
Publicado: (2014)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Analytical Model of ALOHA and Time- and Frequency-Asynchronous ALOHA with Forward Error Correction for IoT Systems
por: Clazzer, Federico, et al.
Publicado: (2022)

Insulin glargine in pediatric patients with type 1 diabetes in Japan
por: Urakami, Tatsuhiko, et al.
Publicado: (2014)

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Buscemi, Silvio, et al.
Publicado: (2019)

Predictors for Mild and Severe Hypoglycemia in Insulin-Treated Japanese Diabetic Patients
por: Sonoda, Nao, et al.
Publicado: (2015)

Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Yamabe, Mizuho
Publicado: (2019)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Insulin Glargine Combined with Oral Antidiabetic Drugs for Asians with Type 2 Diabetes Mellitus: A Pooled Analysis to Identify Predictors of Dose and Treatment Response
por: Gu, Tianwei, et al.
Publicado: (2018)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Aloha - Optics studies by combined kick-response and dispersion fits.
por: Fuchsberger, K
Publicado: (2009)

Slotted ALOHA on LoRaWAN-Design, Analysis, and Deployment
por: Polonelli, Tommaso, et al.
Publicado: (2019)

Optimizing the Performance of Pure ALOHA for LoRa-Based ESL
por: Khan, Malak Abid Ali, et al.
Publicado: (2021)

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
por: Johansen, Odd Erik, et al.
Publicado: (2009)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study)
por: Yamada, Yuichiro, et al.
Publicado: (2017)

Abstract 5: Similar hypoglycemia duration with once-weekly insulin icodec versus insulin glargine U100 in insulin naïve or experienced patients with T2D
por: Manjunath, Aparna, et al.
Publicado: (2022)

Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial
por: Chaykin, Louis, et al.
Publicado: (2019)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus
por: Wang, Jie, et al.
Publicado: (2019)

Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice*
por: Hammer, H, et al.
Publicado: (2007)

Enigmatic relationship between chlorophyll a concentrations and photosynthetic rates at Station ALOHA
por: Laws, E.A., et al.
Publicado: (2016)

Assessing hypoglycemia frequency using flash glucose monitoring in older Japanese patients with type 2 diabetes receiving oral hypoglycemic agents
por: Abe, Hironori, et al.
Publicado: (2019)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study
por: Bu, Shi, et al.
Publicado: (2017)

Improvement of glycemic control without severe hypoglycemia in a type 1 diabetes patient undergoing hemodialysis after a change from insulin glargine to insulin degludec
por: Takahashi, Nobuyuki, et al.
Publicado: (2016)

Frequency and Predictors of Self-Reported Hypoglycemia in Insulin-Treated Diabetes
por: Malkani, Samir, et al.
Publicado: (2017)

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
por: Ott, Christian, et al.
Publicado: (2021)

A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine
por: Belhekar, Mahesh N., et al.
Publicado: (2015)

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
por: Hadjiyianni, I., et al.
Publicado: (2016)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

Experimental Energy Consumption of Frame Slotted ALOHA and Distributed Queuing for Data Collection Scenarios
por: Tuset-Peiro, Pere, et al.
Publicado: (2014)

Aloha Undergraduates: Development and Application of Local & Indigenous Topics into an Undergraduate Public Health Curriculum
por: Nelson-Hurwitz, Denise C., et al.
Publicado: (2019)

Direct-to-Satellite IoT Slotted Aloha Systems with Multiple Satellites and Unequal Erasure Probabilities
por: Tondo, Felipe Augusto, et al.
Publicado: (2021)

Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks
por: Kadowaki, Takashi, et al.
Publicado: (2012)

Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs
por: Baser, Onur, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_osire80f2t0j13ie5tcjemt0a2